OIRA Conclusion of EO 12866 Regulatory Review

RIN: 1117-ZA06         View EO 12866 Meetings	Received Date: 10/10/2024
Title: Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
Agency/Subagency: DOJ / DEA	Stage: Final Rule
Concluded Action: Consistent with Change	Concluded Date: 11/13/2024
Legal Deadline: None	Economically Significant: No
Publication Date:	Unfunded Mandates: No
Major: No	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: No	Small Entities Affected: No
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No